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Editorial Note: The gender ini-
tiative continues with editorials
addressing an increasingly
common clinical syndrome,
heart failure. Sharon Hunt, MD,
gives an insightful overview ad-
dressing the magnitude of the
clinical and economic conse-
quences of heart failure. Mariell
Jessup, MD, and Ileana L. Pin˜a,
MD, continue with an analysis
of possible gender differences
in epidemiology, management,
and outcomes of the syndrome.
Finally, Sara Shumway, MD,
looks at surgical options in
women diagnosed with end-
stage heart failure at various
ages and the implications for
their quality of life. The series
continues in July with editorials
addressing gender differences
in pediatric cardiac surgery.
Nancy A. Nussmeier, MD
Texas Heart Institute
See related editorials on pages 1247
and 1253.
The clinical syndrome of heart failure (HF) is associated with a highprevalence and a high mortality, even in the “modern” era. Hospitaldischarges for HF rose from 377,000 in 1979 to 999,000 in 2000, anincrease of 165%. The rate of this increase is much higher in womenthan in men.1 The reasons for this increase in hospitalizations are likelythe facts that HF is predominantly a disease of the elderly and that there
has been a progressive increase in the segment of the U.S. population that is65 years
of age,2 as well as the fact that HF represents the end stage of a variety of cardiovascular
diseases (coronary artery disease, hypertension, diabetes, valvular disease, sudden
death) that are being more successfully treated in their early stages. The success of early
treatment results in an increasing population, predominantly elderly, of patients with HF
who place an increasing burden on our health care system not only in terms of demand
for complex clinical care but also in terms of cost. It is estimated that the total of direct
and indirect costs for HF in the United States in 2003 will be $24.3 billion.3 In contrast,
in 1999 the estimated cost of human immunodeficiency virus infections, which affect a
much smaller segment of the population, was $28.9 billion.3
Over the past 20 years there has been major progress in devising medical therapy for
HF; some of the largest clinical trials ever conducted have validated the utility first of
angiotensin-converting enzyme inhibitors and later of beta-adrenergic blocking agents in
prolonging life, improving quality of life, and avoiding hospitalizations in patients with
this syndrome. More recent additions to the roster of proven therapies for subsets of
patients have included angiotensin receptor blockers and aldosterone antagonists; mul-
tiple other drugs and modalities are under investigation. Despite these advances, mor-
tality for patients with HF remains high. However, some good news from the Framing-
ham Heart Study published last year documented that the incidence of heart failure has
declined among women, but not among men, over the past 50 years and the survival
rates after the onset of heart failure have improved in both genders.4 Mortality remains
high, however, and compares unfavorably with those associated with many types of
cancer. The 5-year mortality among men after the onset of heart failure declined from
70% in the period from 1950 to 1969 to 59% in the period from 1990 to 1999, and in
women from 57% to 45% between the same time periods.4 The reasons for this
improvement in survival rates are not clear, nor is the actual timing of the improvement.5
The improvement may relate to the introduction of the aforementioned forms of
therapy and also to improving treatment of the underlying causes of HF such as
hypertension.
Although the improvements documented in the Framingham Health Study are quite
encouraging, it is clear that the prolonged survival after the onset of HF coupled with the
“aging” of the population will translate in the future into markedly increased numbers
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of patients requiring complex care for this syndrome. This
situation will likely lead to increasing demand for better med-
ical and surgical therapies to affect outcomes.
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